Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Silence Therapeutics plc

< Previous 1 2 Next >
Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics to Present at Jefferies London Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics to Participate in September Investor Conferences
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics Reports Second Quarter 2023 Results
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics to Present at the Jefferies Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics Reports First Quarter 2023 Results
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics to Present at Guggenheim’s Genomic Medicines and Rare Disease Days
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics to Buyback siRNA Complement Assets
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics to Present at SVB Securities Global Biopharma Conference
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics Reports Third Quarter 2022 Results
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics to Present at Jefferies London Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics to Participate in September Investment Conferences
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics Announces Pricing of Underwritten Offering
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
Silence Therapeutics to Present at Jefferies Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
Tickers SLN
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.